Cargando…

Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma

BACKGROUND: Tertiary lymphoid structures (TLSs) are immune aggregates in peripheral tissues that may support adaptive immune responses. Their presence has been associated with clinical response to checkpoint blockade therapy (CBT), but it is unknown whether TLS have prognostic significance independe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lynch, Kevin T, Young, Samuel J, Meneveau, Max O, Wages, Nolan A, Engelhard, Victor H, Slingluff Jr, Craig L, Mauldin, Ileana S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190052/ https://www.ncbi.nlm.nih.gov/pubmed/34103353 http://dx.doi.org/10.1136/jitc-2020-002273

Ejemplares similares

Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas
por: Edmonds, Nicole L., et al.
Publicado: (2023)

Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts
por: Rodriguez, Anthony B., et al.
Publicado: (2021)

STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment
por: Chelvanambi, Manoj, et al.
Publicado: (2021)

Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer
por: He, Miao, et al.
Publicado: (2023)

Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance
por: Zou, Xuan, et al.
Publicado: (2023)

Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer
por: Masuda, Tsukasa, et al.
Publicado: (2022)

PD-1(+)CXCR5(−)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma
por: Li, Jiang-Ping, et al.
Publicado: (2021)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling
por: Mauldin, Ileana S, et al.
Publicado: (2014)

Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity
por: Subhadarshini, Seemadri, et al.
Publicado: (2023)

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
por: Pollack, Karlyn E, et al.
Publicado: (2020)

TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokines
por: Mauldin, Ileana S, et al.
Publicado: (2013)

Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment
por: Pizzolla, Angela, et al.
Publicado: (2022)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

ZEB1 transcription factor promotes immune escape in melanoma
por: Plaschka, Maud, et al.
Publicado: (2022)

Proliferating CD8(+) T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma
por: Mauldin, Ileana S., et al.
Publicado: (2021)

Meta-Analysis of Single-Cell RNA-Seq Data Reveals the Mechanism of Formation and Heterogeneity of Tertiary Lymphoid Organ in Vascular Disease
por: Sun, Xuejing, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers
por: Kim, Jung Ho, et al.
Publicado: (2021)

IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
por: Weber, Rebekka, et al.
Publicado: (2020)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model
por: Carlson, Peter M, et al.
Publicado: (2021)

HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling
por: Arkhypov, Ihor, et al.
Publicado: (2022)

BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis
por: Frazao, Alexandra, et al.
Publicado: (2020)

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice
por: Bitsch, Rebekka, et al.
Publicado: (2022)

Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages
por: Di Martile, Marta, et al.
Publicado: (2020)

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
por: Meneveau, Max O, et al.
Publicado: (2022)

Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103(+) conventional dendritic cells
por: Zhou, Yifan, et al.
Publicado: (2020)

IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells
por: Magidey-Klein, Ksenia, et al.
Publicado: (2021)

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
por: Martins Nascentes Melo, Luiza, et al.
Publicado: (2023)

Defining the effects of age and gender on clinical immune response to cancer vaccination
por: Ramirez, Adriana, et al.
Publicado: (2014)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
por: Ascierto, Paolo A, et al.
Publicado: (2022)

Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth
por: Heeren, Anne Marijne, et al.
Publicado: (2021)

Endogenous HLA-DQ8αβ programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival
por: Knopick, Peter, et al.
Publicado: (2020)

Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
por: Wen, Jing, et al.
Publicado: (2021)

Intrahepatic CD69(+)Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression
por: Bruni, Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l2dndqj47th1f1uc0a53tus4dt